- Home
- SEVN vs SCPH Comparison
SEVN vs SCPH Comparison
Compare SEVN & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEVN
- SCPH
- Stock Information
- Founded
- SEVN 1986
- SCPH 2013
- Country
- SEVN United States
- SCPH United States
- Employees
- SEVN N/A
- SCPH N/A
- Industry
- SEVN Real Estate Investment Trusts
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- SEVN Real Estate
- SCPH Health Care
- Exchange
- SEVN Nasdaq
- SCPH Nasdaq
- Market Cap
- SEVN 179.3M
- SCPH 173.6M
- IPO Year
- SEVN N/A
- SCPH 2017
- Fundamental
- Price
- SEVN $10.72
- SCPH $5.60
- Analyst Decision
- SEVN Strong Buy
- SCPH Strong Buy
- Analyst Count
- SEVN 3
- SCPH 3
- Target Price
- SEVN $14.75
- SCPH $14.00
- AVG Volume (30 Days)
- SEVN 92.7K
- SCPH 354.9K
- Earning Date
- SEVN 07-28-2025
- SCPH 08-13-2025
- Dividend Yield
- SEVN 13.06%
- SCPH N/A
- EPS Growth
- SEVN N/A
- SCPH N/A
- EPS
- SEVN 1.15
- SCPH N/A
- Revenue
- SEVN $30,074,000.00
- SCPH $41,982,000.00
- Revenue This Year
- SEVN $7.45
- SCPH $108.95
- Revenue Next Year
- SEVN $1.12
- SCPH $73.83
- P/E Ratio
- SEVN $9.33
- SCPH N/A
- Revenue Growth
- SEVN N/A
- SCPH 138.10
- 52 Week Low
- SEVN $10.18
- SCPH $1.94
- 52 Week High
- SEVN $14.66
- SCPH $6.28
- Technical
- Relative Strength Index (RSI)
- SEVN 35.64
- SCPH 75.26
- Support Level
- SEVN $10.68
- SCPH $4.31
- Resistance Level
- SEVN $11.44
- SCPH $6.28
- Average True Range (ATR)
- SEVN 0.32
- SCPH 0.31
- MACD
- SEVN -0.10
- SCPH 0.12
- Stochastic Oscillator
- SEVN 6.85
- SCPH 71.70
About SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in the business of originating and investing in floating rate first mortgage loans secured by the middle market and transitional commercial real estate. Its primary objective is to balance capital preservation with generating risk-adjusted returns.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.